Minocycline · oral capsule
Antibiotic
Approved uses
Trachoma and inclusion conjunctivitis caused by Chlamydia trachomatis
200 mg orally initially, then 100 mg every 12 hours (the usual adult dosage; the label gives no trachoma-specific regimen)
Intracranial hypertension (pseudotumor cerebri), with papilledema, is the ocular hazard to watch for
Contraindications
This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or to any of the components of the product formulation.
Minocycline hydrochloride capsules, 50 mg and 75 mg in bottles of 100, and 100 mg in bottles of 50
The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including minocycline, have a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative organisms. Cross-resistance of these organisms to tetracycline is common.
Warnings & Precautions
- Permanent tooth discoloration: The use of tetracycline-class drugs during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown); enamel hypoplasia has also been reported. Tetracyclines should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated.
- Fetal harm: Minocycline, like other tetracycline-class antibiotics, can cause fetal harm when administered to a pregnant woman; if it is used during pregnancy or the patient becomes pregnant while taking it, the patient should be apprised of the potential hazard to the fetus. Animal studies indicate tetracyclines cross the placenta and can have toxic effects on the developing fetus, and the safety of minocycline during pregnancy has not been established.
- Decrease in fibula growth rate: All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in premature human infants given oral tetracycline 25 mg/kg every six hours, and it was reversible when the drug was discontinued.
- Photosensitivity: Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines and has been reported with minocycline; patients apt to be exposed to direct sunlight or ultraviolet light should be advised of it, and treatment should be discontinued at the first evidence of skin erythema.
- Intracranial hypertension (pseudotumor cerebri): it presents with headache, blurred vision, diplopia and vision loss, and papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. It usually resolves after stopping, but permanent visual loss is possible and pressure can stay raised for weeks, so monitor until stable; any visual disturbance during treatment warrants prompt eye examination. Avoid use with isotretinoin.
- Lightheadedness, dizziness, or vertigo: These central nervous system side effects have been reported; patients who experience them should be cautioned about driving vehicles or using hazardous machinery. The symptoms may disappear during therapy and usually disappear rapidly when the drug is discontinued.
- DRESS and fixed drug eruptions: Drug rash with eosinophilia and systemic symptoms (DRESS), including fatal cases, has been reported with minocycline. Fixed drug eruptions have occurred with minocycline and other tetracyclines, and worsening severity on later doses, including generalized bullous fixed drug eruption, has been observed with other tetracyclines. If severe skin reactions occur, discontinue minocycline immediately and institute appropriate therapy.
- Lupus-like syndrome: a transient lupus-like syndrome and serum sickness-like reactions have been reported, some fatal; stop at once if either is recognized.
- Increased BUN (antianabolic action): The antianabolic action of the tetracyclines may cause an increase in blood urea nitrogen (BUN); in patients with markedly impaired renal function, higher serum levels may lead to azotemia, hyperphosphatemia, and acidosis, so monitor creatinine and BUN and do not exceed 200 mg in 24 hours. If renal impairment exists, even usual doses may lead to systemic accumulation of the drug and possible liver toxicity.
- Clostridium difficile-associated diarrhea (CDAD): Reported with nearly all antibacterial agents, including minocycline, and may range from mild diarrhea to fatal colitis. Consider CDAD in any patient with diarrhea after antibiotic use; it has been reported over two months later. If suspected or confirmed, antibiotics not directed against C. difficile may need to be stopped; start fluid and electrolyte management, protein supplementation, C. difficile treatment and surgical evaluation as clinically indicated.
- Hepatotoxicity: it has been reported with minocycline, so use with caution in hepatic dysfunction and with other hepatotoxic drugs.
- Superinfection: Use may result in overgrowth of non-susceptible organisms, including fungi; if superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted.
- Drug-resistant bacteria: Prescribing minocycline in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Common Side Effects
Because absorption is virtually complete, lower-bowel effects such as diarrhea are infrequent. Reported reactions include anorexia, nausea, vomiting and dyspepsia; esophagitis and esophageal ulceration, mostly when taken just before bed (give with fluids); dizziness, vertigo and headache; rashes and photosensitivity; skin and mucous membrane pigmentation and tooth discoloration; brown-black microscopic discoloration of the thyroid gland with prolonged use; raised liver enzymes, hepatitis (including autoimmune) and liver failure, sometimes fatal; and tinnitus and decreased hearing. Thyroid cancer has been reported in the post-marketing setting; when therapy is given over prolonged periods, monitoring for signs of thyroid cancer should be considered.
Pregnancy: There are no adequate and well-controlled studies in pregnant women; minocycline, like other tetracycline-class antibiotics, crosses the placenta and may cause fetal harm. Use during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth, and tetracyclines form a stable calcium complex in any bone-forming tissue. Rare spontaneous reports of congenital anomalies including limb reduction have been reported postmarketing, but no conclusion on causal association can be established.
Lactation: Tetracyclines are excreted in human milk; because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Not recommended below 8 years of age unless the expected benefits outweigh the risks, because use during tooth development may cause permanent discoloration of the teeth.